HC Wainwright reiterates Buy on Pharming, lifts $37 target
HC Wainwright & Co. reiterated a Buy rating on Pharming with a $37.00 price target, implying upside of 3,736.6% from the Sep 22 close of $0.96.
HC Wainwright & Co. reiterated its Buy rating on Pharming and set a price target of $37.00. The target implies an upside of 3736.6% from the Sep 22 close of $0.96. Key takeaways from the analyst note included positive Phase 2 data for leniolisib, according to the note.